Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 29 Edition
June 28 Edition
NfL, GFAP elevated post-COVID
Long-term data for anti-CD20 agents
Improved cognitive processing speed with ofatumumab
Cognitive impairment may predict physical disability
B cell kinetics during pregnancy
Clinical tip of the day
Read More
Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 30 Edition
June 28 Edition
COVID vaccine response with ofatumumab
Delayed time to wheelchair with siponimod
HSCT – the Swiss experience
Vaccine response to BTK inhibitors
Clinical tip of the day
Read More
Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 30 Edition
June 29 Edition
Relapses uncommon after COVID vaccination
The aging MS patient
Ocrelizumab EID
Natalizumab EID
Clinical tip of the day
Read More
The U.S. Food and Drug Administration will meet later this month to consider approval of two bivalent COVID-19 booster vaccines that are reportedly effective against the Omicron variant (B.1.1.529). Both boosters were developed by Moderna and are variations of the company’s original mRNA-1273 vaccine. Read More